COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN

被引：3
|
作者：
Peral, C. [1 ]
Cordido, F. [2 ]
Gimeno, V [3 ]
Sanchez-Cenizo, L. [1 ]
Mir, N. [1 ]
Parrondo, J. [4 ]
机构：
[1] Pfizer SLU, Alcobendas, Madrid, Spain
[2] Hosp A Coruna, La Coruna, Spain
[3] Hosp Miguel Servet, Zaragoza, Spain
[4] JParrondo Hlth, Madrid, Spain
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.901
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY75
引用
收藏
页码：A557 / A558
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [2] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [3] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    Villa, G.
    Hernandez-Pastor, L. J.
    Guix, M.
    Lavernia, J.
    Cuesta, M.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 24 - 33
  • [4] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    G. Villa
    L. J. Hernández-Pastor
    M. Guix
    J. Lavernia
    M. Cuesta
    [J]. Clinical and Translational Oncology, 2015, 17 : 24 - 33
  • [5] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [6] A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    [J]. GACETA SANITARIA, 2009, 23 : 200 - 201
  • [7] Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
    Chay, Junxing
    Tung, Joshua Yi Min
    Su, Rebecca Jade
    Aslim, Edwin Jonathan
    Wong, Callix
    Swan, Georgia
    Chua, Wei Jin
    Ho, Henry Sun Sien
    Finkelstein, Eric Andrew
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1269 - 1277
  • [8] Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung
    Zhu, Jun
    He, Wei
    Ye, Ming
    Fu, Jie
    Chu, Yun-Bo
    Zhao, Yi-Yang
    Zhang, Yan-Jun
    Kuo, David
    Wu, Bin
    [J]. FUTURE ONCOLOGY, 2018, 14 (27) : 2833 - 2840
  • [9] Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
    Chay, J.
    Su, R.
    Tung, J. Y. M.
    Aslim, E. J.
    Wong, C.
    Swan, G.
    Chua, W. J.
    Ho, S. S. H.
    Finkelstein, E. A.
    [J]. EUROPEAN UROLOGY, 2023, 83 : S52 - S52
  • [10] Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer
    Lam, Simon W.
    Wai, Maya
    Lau, Jessica E.
    McNamara, Michael
    Earl, Marc
    Udeh, Belinda
    [J]. PHARMACOTHERAPY, 2017, 37 (01): : 94 - 103
12345